24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
PARIBLIEVA 150MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | PARIBLIEVA 150MG |
|---|---|
| Composition | Olaparib Tablets 150mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
PARIBLIEVA 150MG (Olaparib Tablets 150mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is a prescription targeted anticancer medicine containing Olaparib 150 mg, a highly advanced PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of several types of cancer associated with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Olaparib is widely used in modern precision oncology to help slow cancer growth, delay disease progression, and improve treatment outcomes in eligible patients.
Cancer cells with BRCA gene mutations often have difficulty repairing damaged DNA. PARIBLIEVA 150 MG works by blocking PARP enzymes, which cancer cells use to repair their DNA. When both repair mechanisms are disrupted, cancer cells are unable to survive and eventually die. This targeted approach allows Olaparib to selectively attack cancer cells while minimizing damage to healthy tissues.
PARIBLIEVA 150 MG has become an important treatment option in personalized cancer care and is commonly prescribed for patients whose tumors carry specific genetic abnormalities. Genetic testing is often performed before treatment to determine whether a patient is likely to benefit from Olaparib therapy.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Olaparib specifically targets cancer cells with defective DNA repair pathways. This precision-based mechanism has transformed the treatment landscape for several difficult-to-treat cancers.
PARIBLIEVA 150 MG is commonly prescribed for:
The medicine may be used as maintenance therapy after successful cancer treatment or as part of long-term disease management plans, depending on the patient's condition and oncologist’s recommendations.
Manufactured according to stringent pharmaceutical quality standards, PARIBLIEVA 150 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Olaparib therapy require routine monitoring, including blood tests, kidney and liver function assessments, and regular clinical evaluations to ensure safe and effective treatment.
Due to its targeted mechanism and proven clinical benefits, PARIBLIEVA 150 MG has become a valuable treatment option in modern cancer care worldwide.
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is primarily used in the treatment and management of cancers associated with BRCA mutations and DNA repair defects.
The medicine is widely prescribed for advanced and recurrent ovarian cancer, particularly in patients with BRCA mutations.
Olaparib helps reduce the risk of cancer recurrence following successful initial treatment.
The medicine is used in eligible patients with hereditary BRCA-mutated breast cancer.
Doctors may prescribe Olaparib for advanced breast cancer that has spread to other parts of the body.
The medicine may be used in patients with BRCA-mutated pancreatic cancer.
Olaparib may be prescribed for selected patients with advanced prostate cancer carrying specific genetic mutations.
The medicine supports personalized treatment strategies based on genetic testing.
Olaparib helps delay disease progression and maintain treatment response.
Olaparib belongs to a class of medicines known as PARP Inhibitors.
PARIBLIEVA works by:
This targeted mechanism helps selectively destroy cancer cells with defective DNA repair pathways.
Like all medicines, PARIBLIEVA 150 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Tiredness and weakness are among the most frequently reported side effects.
Patients may experience mild to moderate nausea during treatment.
Low red blood cell counts may occur and require monitoring.
Some individuals may experience vomiting.
Reduced appetite may affect nutritional intake.
Digestive disturbances may occur during treatment.
Headaches may occasionally develop.
Mild to moderate stomach discomfort may occur.
The medicine may affect red blood cells, white blood cells, and platelets.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
BRCA mutation and other genetic testing results influence therapy decisions.
Doctors may adjust therapy according to effectiveness and patient tolerance.
Kidney and liver function may affect dosage recommendations.
Drug interactions may require dosage adjustments.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically directed by a healthcare professional.
It is used for the treatment of certain ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations or specific DNA repair defects.
Olaparib is a targeted anticancer medicine known as a PARP inhibitor that prevents cancer cells from repairing damaged DNA.
No. It is a targeted therapy and works differently from traditional chemotherapy medicines.
Genetic testing helps identify patients with BRCA mutations or other DNA repair abnormalities who are most likely to benefit from Olaparib therapy.
Yes. It is commonly used as maintenance treatment in eligible ovarian cancer patients after successful initial therapy.
Yes. The medicine may lower red blood cells, white blood cells, and platelet counts, requiring regular monitoring.
Yes. Routine blood tests and clinical evaluations are important throughout treatment.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.